Phase III, multicenter, randomized, open-label, endpoint-blind study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer-associated VTE. ASTER
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ANTHOS THERAPEUTICS
- Phase: III
- Execution start: 26/04/2022
- End of execution: 06/05/2024
- PI: RAQUEL LUQUE CARO